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Setting: The study was conducted at Mulago Hospital, Kampala, Uganda.
Objective: As chronic respiratory disease (CRD) is a huge, growing burden in Africa, with few 
available treatments, we aimed to design and evaluate a culturally appropriate pulmonary reha-
bilitation (PR) program in Uganda for people with post-tuberculosis lung disorder (p-TBLD).
Design: In a pre–post intervention study, a 6-week, twice-weekly PR program was designed for 
people with p-TBLD. Outcome measures included recruitment, retention, the Clinical COPD 
Questionnaire (CCQ), tests of exercise capacity, and biometrics. Given this was a developmental 
study, no formal statistical significance testing was undertaken.
Results: In all, 34 participants started PR and 29 (85%) completed all data collection. The 
mean age of the 29 participants was 45 years, and 52% were female. The mean (95% confidence 
interval) CCQ score at baseline was 1.8 (1.5, 2.0), at the end of PR was 1.0 (0.8, 1.2), and at 
6 weeks after the end of PR was 0.8 (0.7, 1.0). The Incremental Shuttle Walking Test (ISWT) 
was 299 m (268.5, 329.4) at baseline, 377 (339.6, 413.8) at the end of PR, and 374 (334.2, 
413.5) at 6 weeks after the end of PR. Improvements were seen in measures of chest pain; 13/29 
(45%) participants reported chest pain at baseline but only 7/29 (24%) at the end of PR, and in 
those with persistent pain, the mean pain scores decreased. Mild hemoptysis was reported in 
4/29 (17%) participants at baseline and in 2/29 (7%) at the end of PR.
Conclusion: PR for people with p-TBLD in Uganda was feasible and associated with clinically 
important improvements in quality of life, exercise capacity, and respiratory outcomes. PR uses 
local resources, requires little investment, and offers a new, sustainable therapy for p-TBLD in 
resource-limited settings. With the rising global burden of CRD, further studies are needed to 
assess the value of PR in p-TBLD and other prevalent forms of CRD.
Keywords: tuberculosis, exercise training, self-management, nonpharmacological intervention
Introduction
The World Health Organization considers the control and management of noncom-
municable diseases (NCDs) a top priority – NCDs cause more deaths than all other 
causes combined and are projected to increase from 38 million worldwide in 2012 
to 52 million by 2030.1 Lung diseases are preeminent, and COPD is now the third 
leading cause of death globally and the ninth highest cause of disability.1 The 
burgeoning prevalence of chronic respiratory disease (CRD) is fueled by an aging 
population, the combination of respiratory infections such as tuberculosis (TB) with 
human immunodeficiency virus (HIV), tobacco smoking, household air pollution, and 
nutritional impairment.2–4
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One major cause of CRD is post-tuberculosis lung disor-
der (p-TBLD). In a study in the USA, the long-term sequelae 
of pulmonary tuberculosis (PTB) dwarf the costs and disease 
burden of acute infection.5,6 In Africa, the problem may be 
worse; permanent extensive lung damage after PTB is com-
mon and is associated with delayed diagnosis, multidrug 
resistance, and nonadherence to treatment.7 In addition, air 
pollution (both indoor and outdoor) and tobacco smoking 
are pervasive problems that add to damage to lung paren-
chyma from repeated infections.2 An informal notes review 
of sequential patients attending respiratory clinics in Mulago 
Hospital, a tertiary referral center in Uganda, showed that 
30% of those attending the TB clinic had p-TBLD and 12% of 
those attending general chest clinics had p-TBLD as the main 
presenting problem. The range of clinical features included 
dyspnea, chest pain, and hemoptysis, similar to patients seen 
in Rwanda.8 Currently, there is little or no effective treatment 
for people with p-TBLD in Africa.
People with CRD are prone to develop musculoskeletal 
dysfunction related to physical inactivity and systemic inflam-
mation, compounded by impaired nutrition.9 Such people 
enter a vicious circle with falling body weight, progres-
sive morbidity, and increased mortality, accelerated by the 
accompanying anxiety, depression, and social isolation. 
Symptoms such as breathlessness, fatigue that comes with 
deconditioning, demotivation, and psychosocial isolation 
have been shown previously to be amenable to pulmonary 
rehabilitation (PR).10,11
PR is a program of individually prescribed and supervised 
exercise, education, and self-management activities. There 
is strong evidence that PR improves health status, exercise 
capacity, and social functioning, and PR is recommended 
in international guidelines10,11 with supporting information 
on delivery.12 PR may be delivered using existing local staff 
such as nurses, doctors, physiotherapists, and clinic staff and 
allows patients to help themselves and to help each other. 
As there is no need for major capital outlay or equipment, 
PR has the potential to be a sustainable and scalable inter-
vention in resource-limited settings. However, the potential 
for PR to improve CRDs, such as COPD and p-TBLD, in 
low- to middle-income countries (LMICs) has not been 
properly tested. A literature review found no evidence of 
PR being used in sub-Saharan Africa to treat p-TBLD or 
indeed any CRD, apart from an observational study in 2001 
in 38 people with asthma and COPD,13 and for patients 
undergoing treatment for active pulmonary TB, a pilot trial of 
PR in South Africa showed some promise.14 Globally, there 
is little evidence of PR being used to treat p-TBLD;15 there 
were two observational studies of PR from Japan in elderly 
people with p-TBLD, one with 32 participants and one with 
37 participants, and more recently one from Colombia includ-
ing 11 p-TBLD patients.16–18
In 2014, we conducted a successful feasibility study of 
running PR for people with p-TBLD in Kampala. We designed 
and established a process of recruitment, assessment, inter-
vention, and follow-up and trained local staff to deliver the 
program. In the 18 participants completing the feasibility 
study, clinically important improvements were seen in the 
quality of life, exercise capacity, and biometrics. An unex-
pected reduction in the number of participants reporting chest 
pain and hemoptysis was also noted.
The aim of our current study was to design a culturally 
appropriate program for people with p-TBLD and examine 
impact of PR on quality of life, exercise capacity, and other 
impacts to inform the development of a larger trial.
Patients and methods
study design
This study was a pre- and post interventional cohort study.
Participants
Patients attending the respiratory outpatients department in 
Mulago Hospital were screened, and those potentially suitable 
were invited to take part in more detailed assessments.
The inclusion criteria were previous treatment for pul-
monary TB and breathlessness reaching Medical Research 
Council (MRC) dyspnea scale grade 2 or higher. We excluded 
those with sputum positive testing for TB (GeneXpert), 
unstable cardiovascular disease, and locomotor difficul-
ties that precluded exercise; those who were unwilling or 
unable to attend a PR program; and those unable to provide 
informed consent.
assessments
The assessments comprised a medical review, physical 
examination, and review of relevant investigations (eg, chest 
X-ray, spirometry, sputum for TB using GeneXpert, HIV 
test). Written informed consent was obtained, and in the 
case of participants aged ,18 years, the parents provided 
written informed consent. Patients meeting inclusion criteria 
underwent further rehabilitation assessments including 
demographics, questionnaires (Karnofsky scale,19 MRC 
dyspnea scale,20 Clinical COPD Questionnaire [CCQ],21 
and Patient Health Questionnaire-9 [PHQ-9]),22 biometrics, 
and tests of exercise capacity (Incremental Shuttle Walking 
Test [ISWT]23 and Five Times Sit-to-Stand test).24 We also 
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captured details of symptoms, including a rating scale of 
chest pains based on the Brief Pain Inventory. To ensure that 
patients were suitable, a final review of all patients being 
assessed was undertaken by a physiotherapist and physician, 
with particular emphasis on those with a Karnofsky score19 
of 0–30 (too sick) or .80 (not disabled) or an ISWT distance 
of .600 m at the baseline assessment.
An extensive range of qualitative assessments were 
undertaken and will be reported separately.
Pr program
Based on conventional PR models, the program was con-
ducted twice weekly for 6 weeks with groups of 10–13 
participants and consisted of exercise and education. The 
day-to-day program was overseen by a senior physiothera-
pist in collaboration with a specialist nurse, counselor, and 
doctor. The sessions were conducted in the physiotherapy 
department, which included an outdoor but shaded walking 
area. The program lasted ~2 hours; drinks and light food 
were provided.
The exercise program followed international guidance for 
PR.10,12 The main focus of the training program was aerobic 
lower limb exercise. This was predominately walking based, 
and the prescription was based upon initial performance on 
the ISWT. The intensity of the program was set at 80% of 
peak performance on the ISWT. The exercise regime was 
individually prescribed, monitored, and increased as the pro-
gram progressed under the supervision of the physiotherapist 
(RK). The aim was to complete 30 minutes of walking at the 
set speed five times a week. At each session, participants 
also completed resistance training for the upper and lower 
limbs. The stations included sit-to-stand, step-ups, biceps 
curls, and upright rowing with weights. The weights were 
increased as each participant achieved three sets of eight 
to ten repetitions of each exercise. Exercise was followed 
by group warm down and education. Participants received 
instructions on a home exercise regime (both aerobic and 
resistance), and they kept a diary of the exercises undertaken 
at home. After completion of the program, participants 
were encouraged to continue with the exercises in the long 
term. The program deployed little specialist equipment 
and was improvised for the resistance training, particularly 
at home.
The education component included information on 
pulmonary TB specifically and CRD generally and covered 
the causes and effects of CRD, self-management, avoiding 
adverse exposures, exercise, and diet. The PR program oper-
ated to the British Thoracic Society PR Quality Standards.12 
Participants were provided with an information sheet on the 
PR program and details of exercises to do at home during 
and after the program. (A video about the program is avail-
able at https://www.plymouth.ac.uk/research/primarycare/
fresh-air.)
Patients and hospital staff were involved in the design to 
ensure that the venue, timing, and access were addressed. The 
PR program was strongly based on Western evidence-based 
models, and relatively little cultural adaptation was wanted 
or needed. For example, using local music or dance to make 
the program more interesting and appropriate was rejected 
by both participants and staff. The adaptations to make the 
program relevant to the health care setting were not difficult 
as first, it was delivered by local clinicians in the National 
Referral Hospital and second, the UK model that the service 
was developed from was used with minimal resources.
statistical methods
Outcomes are summarized descriptively, with estimates 
accompanied by 95% confidence intervals where appropriate, 
and presented in tables and graphs. Given this was a develop-
ment study, no statistical significance testing was undertaken, 
as the study was not designed a priori to have sufficient 
statistical power to detect differences in clinical outcomes; 
however, where appropriate, the average changes in clinical 
outcomes are discussed in relation to published minimal 
clinically important differences (MCIDs).
ethical approval
Ethical approval was obtained from the Mulago Hospital 
Research and Ethics Committee MREC number 440 
(28.10.2013).
Trial registration
The study was registered at the International Standard 
Registered Clinical/soCial sTudy Number (ISRCTN) registry 
(http://www.isrctn.com) under number ISRCTN14312425.
Results
In total, 113 patients attending the general respiratory out-
patients department of Mulago Hospital were assessed using 
a screening form for potential p-TBLD, of whom 56 met the 
screening criteria of MRC dyspnea scale 2 or above and pre-
vious TB treatment, and were further assessed for suitability 
for this study. Of the 56 patients, 36 met all the entry criteria, 
34 started PR in three groups, and 29 completed the program 
and all data collection. Of the five participants failing to 
complete the 6-week program, three did not reappear for 
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unknown reasons, one died, and one was diagnosed with 
recurrent PTB infection and admitted for treatment.
The baseline characteristics of the 29 participants who 
completed the program are shown in Table 1. Just over half 
of the participants (51.7%) were female, and the mean age 
was 45 years, range 17–69 years. Spirometry showed 14/29 
(48.2%) participants had obstruction, 10/29 (34.4%) had 
restriction, and 5/29 (17.2%) had normal results at baseline. 
Reversibility testing was performed on those with forced 
expiratory volume (FEV):forced vital capacity (FVC) 
ratio ,0.7: of the 12 participants undertaking this, only 
two showed reversibility of $12% and .200 mL change 
in forced expiratory volume in 1 second (FEV
1
). Further 
spirometric data are shown in Table 2. Before exercise, 
7/29 (24.1%) participants had resting oxygen saturations 
of ,93% versus 11/29 (37.9%) participants after completing 
the maximal exertion (the ISWT).
Health status results showed that after completing PR, 
the mean improvement in the CCQ was 0.95 (Table 3) and 
the total and domain score improvements all exceeded the 
MCID of -0.4.25 The mean improvement in the ISWT was 
90 m (MCID 48 m), and the improvement in Sit-to-Stand 
test time was 2.5 seconds, also beyond the MCID (MCID 
2.3 seconds).26 At the individual level, 17/29 (59%) partici-
pants showed improvements in ISWT and 18/29 (61%) par-
ticipants in the Sit-to-Stand test above the respective MCIDs. 
The mean Karnofsky scale score, which rates people’s status 
between 0 (dead) and 100 (normal health), improved by 
13.8%. Depression scores on the PHQ-9 were very low at 
baseline and almost zero after the program; the proportion of 
participants with a score of $5 was 7/29 (24.1%) at baseline 
and 0/29 at the end of PR and after 6 weeks.
Biometrics also showed that from a low baseline, there 
were modest increases in average body mass index (BMI) 
and mid-upper arm circumference (Table 3). Three out of 
14 participants whose BMI was ,20 at baseline had BMI 
scores in the normal range (20–25) immediately and 6 weeks 
after rehabilitation.
Measures of participants’ symptoms showed a reduction 
in the proportion with chest pain and hemoptysis but not with 
cough (Table 4). Chest pain was reported in 13/29 (45%) 
participants prior to PR but only in 7/29 (24%) participants 
after 6 weeks; thus, the pain was abolished in nearly half the 
people completing PR. Group mean chest pain scores fell 
(Figure 1), and even in the participants who still reported pain 
at the study end, the pain severity scores fell in 7/13 (54%) 
participants. The nature of the pain was consistent in par-
ticipant reports; it was described as sharp, severe, and worse 
with lying down. For many participants, pain was as big a 
problem as breathlessness, and its reduction was reported as 
a great benefit. Mild hemoptysis was reported in 4/29 (17%) 
participants at baseline and in 2/29 (7%) participants at the 
end of PR and after 6 weeks.
Discussion
In this study, we aimed to examine the impact of a PR pro-
gram in Uganda for people with p-TBLD. We found that PR 
participants showed a high level of participation and comple-
tion, and clinically important improvements were seen in 
maximum exercise tolerance and quality of life.
At 85%, the PR completion rates in our study were high; 
other studies have shown that completion rates of programs 
of similar duration usually vary between 60% and 90%, but 
may be as low as 30%.10,27,28 The national report on PR in 
England and Wales involving .7,000 patients showed 71% 
of those enrolled completed the program.29 The high comple-
tion rates in the current study occurred despite profound 
transport problems in Kampala, and travel problems have 
Table 1 Background characteristics of p-TBlD patients (n=29)
Characteristics Value
gender – female, n (%) 14 (51.7)
age group (years), n (%)
17–35 6 (20.7)
36–50 13 (44.8)
51–69 10 (34.5)
age in years, mean (sD) 45 (13)
highest level education, n (%)
none/incomplete primary 11 (37.9)
Complete primary/incomplete secondary 9 (31)
Complete secondary/tertiary 9 (31)
Occupation, n (%)
Unemployed 9 (31)
Others 20 (69)
ever smoked, n (%) 10 (34.5)
If smoked, duration smoked in years, median (IQr) 15.5 (18)
exposed to biomass, n (%) 12 (41.4)
If exposed to biomass
number of hours exposed per day, median (IQr) 2 (2)
number of years exposed, median (IQr) 10 (15)
Abbreviations: p-TBlD, post-tuberculosis lung disorder; IQr, interquartile range.
Table 2 Baseline spirometric data on 29 participants
Variables Prebronchodilator, 
mean (SD)
Postbronchodilator, 
mean (SD)
FeV1 (l) 1.40 (0.56) 1.42 (0.54)
FeV1% 56.8 (25.0) 58.1 (25.2)
FVC (l) 2.08 (0.60) 2.13 (0.61)
FVC% 70.4 (21.8) 72.0 (21.63)
FeV:FVC 0.68 (0.19) 0.67 (0.19)
Abbreviations: FeV1, forced expiratory volume in 1 second; FeV1%, forced 
expiratory volume in 1 second as a percentage of predicted; FVC, forced vital 
capacity; FVC%, forced vital capacity as a percentage of predicted.
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been associated previously with higher dropout rates.28 While 
it was intended that participants would live within 10 km of 
the hospital, some participants came .50 km by bus twice a 
week and still attended regularly. This reflects an enthusiasm 
to take part seen in the majority of participants.
Care is needed in interpreting outcomes in a development 
study, which is not adequately statistically powered, and in 
a pre–post cohort design, causality cannot be implied. How-
ever, the changes associated with PR in outcomes such as 
disease-specific quality of life or exercise capacity were simi-
lar to, or larger than, the changes seen in conventional PR for 
COPD in Western countries. The main clinical outcomes 
assessed were the ISWT and the CCQ. The mean change in 
ISWT observed in this study of 79 m is well above the MCID 
of 48 m and greater than the difference between intervention 
and control groups of 40 m (range 22.4–57.1 m higher in 
eight studies) reported in a Cochrane review.30 Similarly for 
the CCQ, the magnitude of the changes seen in this devel-
opment study is comparable or higher than other published 
data such as routinely collected data from a London teaching 
hospital program.31 Our data versus those from London were 
as follows: CCQ total -0.95 versus -0.5 and CCQ domain 
scores: symptoms -0.93 versus -0.1, mental state -1.22 
versus 0.1, and CCQ functional -0.83 versus -0.2.
This study was conducted in patients with p-TBLD in 
Uganda, and there are many differences in such patients 
compared to patients with COPD in the Western World. 
They have different pathology, socioeconomic status, and 
limited access to conventional drug treatments. The desire 
to take part in the study was strong as there was little else 
on offer for them and the service was free. Many expressed 
gratitude, and this may have influenced the results of self-
reported questionnaires. The participants in this program had 
TB-related lung damage, but many also had exposure to air 
Table 3 Mean (95% CI) of health status, exercise capacity, and biometric outcomes for 29 participants who completed data collection 
at all three time points
Outcome measures Baseline End of PR Change from 
baseline to end 
of PR
6 weeks after end 
of PR
Change from 
baseline to 
6 weeks after end 
of PR
CCQ total score 1.88 (1.59, 2.17) 0.93 (0.76, 1.10) -0.95 (-1.18, -0.72) 0.79 (0.63, 0.96) -1.09 (-1.34, -0.83)
CCQ symptom score 2.03 (1.69, 2.38) 1.10 (0.88, 1.33) -0.93 (-1.23, -0.63) 0.95 (0.71, 1.19) -1.08 (-1.39, -0.79)
CCQ mental state score 1.98 (1.49, 2.47) 0.76 (0.47, 1.04) -1.22 (-1.56, -0.89) 0.52 (0.33, 0.70) -1.46 (-1.96, -0.97)
CCQ functional state score 1.67 (1.40, 1.95) 0.84 (0.69, 1.00) -0.83 (-1.08, -0.57) 0.77 (0.60, 0.93) -0.90 (-1.16, -0.65)
PhQ-9 total score 3.24 (1.24, 5.24) 0.03 (-0.04, 0.11) -3.21 (-5.10, -1.31) 0.07 (-0.07, 0.21) -3.17 (-5.05, -1.29)
Karnofsky score 75.86 (73.70, 78.02) 89.66 (88.05, 91.26) 13.79 (12.00, 15.59) 90.34 (88.19, 92.50) 14.48 (11.8, 17.19)
IsWT (m) 312.41 (275.95, 348.88) 402.41 (357.74, 447.08) 90.00 (56.50, 123.50) 402.07 (353.84, 450.29) 89.66 (49.32, 129.99)
Borg score after IsWT 6.48 (5.68, 7.28) 4.36 (3.55, 5.17) -2.12 (-2.98, -1.26) 4.52 (3.65, 5.39) -1.96 (-2.93, -1.00)
sit-to-stand time (seconds) 10.45 (9.29, 11.61) 7.90 (7.01, 8.78) -2.55 (-3.69, -1.41) 7.03 (6.53, 7.54) -3.42 (-4.46, -2.37)
BMIa (kg/m2) 20.86 (18.92, 22.81) 21.49 (19.59, 23.40) 0.63 (0.23, 1.03) 21.77 (19.92, 23.61) 0.91 (0.42, 1.39)
Mid upper arm 
circumference (cm)
25.27 (23.83, 26.72) 25.33 (23.10, 27.56) 0.06 (-1.64, 1.75) 25.92 (24.46, 27.39) 0.65 (0.21, 1.10)
Note: aBased on 28 patients.
Abbreviations: CI, confidence interval; PR, pulmonary rehabilitation; CCQ, Clinical COPD Questionnaire; PHQ-9, Patient Health Questionnaire-9; ISWT, Incremental 
shuttle Walking Test; BMI, body mass index.
Table 4 number (%) of participants reporting cough, chest pains, 
and hemoptysis in 29 p-TBlD participants who completed data 
collection at all three time-points 
Symptoms Summary 
measure
Number (%) at time
Baseline End of 
PR
6 weeks 
after end 
of PR
experience pain in chest? Yes 13 (44.8) 9 (31) 7 (24.1)
suffer from hemoptysis? Yes 5 (17.2) 2 (6.9) 2 (6.9)
have cough? none 17 (58.6) 14 (48.3) 17 (58.6)
Mild 8 (27.6) 14 (48.3) 10 (34.5)
Moderate 4 (13.8) 1 (3.4) 2 (6.9)
severe 0 0 0
Abbreviations: p-TBlD, post-tuberculosis lung disorder; Pr, pulmonary rehabili-
tation.
Figure 1 Mean chest pain severity scores before, after and six weeks after Pr (n=29).
Abbreviation: Pr, pulmonary rehabilitation.
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pollution and tobacco smoke and nearly half had obstructive 
spirometry. Many were unable to work, had poor nutritional 
status, and may have impaired defense against damage: we 
believe that there is a complex interaction between infection, 
air pollution, and deprivation in causing chronic disease. 
PR, by improving ability to work and gain of weight and 
strength, may reverse the vicious circles and substantially 
improve health status.
This study confirmed the novel finding of the preceding, 
unpublished feasibility study that participants with p-TBLD 
noted reductions in chest pain after PR. Chest pain in p-TBLD 
is not widely reported, but it is present in 20% in a series 
of p-TBLD adult patients in Rwanda,8 and the rate was 
similar in an informal notes review we conducted in Mulago 
Hospital when designing the recruitment strategy. In this 
study, where participants had to have persistent breathless-
ness at baseline to be eligible to participate, 61% reported 
chest pain before and 25% 6 weeks after the end of PR. 
Of those with persistent pain after PR, mean pain severity 
scores were reduced in 57% of participants. The mechanism 
for this, and the less marked falls in hemoptysis, is not clear, 
and further adequately powered studies are needed to confirm 
the findings and examine underlying mechanisms.
Guidelines on TB treatment have largely omitted men-
tion of the problem of p-TBLD, including the scale of the 
problem, how it is identified and assessed, and how the asso-
ciated symptoms and disability can be improved. This study 
shows that PR is a potentially important treatment option for 
many people with p-TBLD, a finding that requires confirma-
tion from larger controlled trials.
Conclusion
p-TBLD is a widespread problem in many LMICs and affects 
people of all ages. There are no effective treatments currently 
available. Especially for the young, this is a huge problem 
in terms of disability, loss of income, and social isolation. 
PR addresses disability, exercise capacity, and social par-
ticipation. This development study confirms that culturally 
appropriate PR in Uganda shows potential to improve a 
range of patient-related outcomes and health status and was 
associated with unexpected improvements in chest pains and 
hemoptysis. These findings need confirmation in adequately 
powered controlled trials.
Acknowledgments
This research was supported by the National Institute for 
Health Research (NIHR) Collaboration for Leadership in 
Applied Health Research and Care South West Peninsula 
at the Royal Devon and Exeter NHS Foundation Trust. 
The views expressed are those of the author(s) and not 
necessarily those of the NHS, the NIHR, or the Department 
of Health. This study was a performed in association with 
the Fresh Air group and was a demonstration project for the 
World Health Organization (Global Alliance against CRDs). 
The study was funded by a Joint Global Health Development 
grant from the UK Medical Research Council, the Wellcome 
Foundation and the UK Government Department for Inter-
national Development fund. The authors acknowledge the 
contribution made by Dr William Worodria to the conduct 
of the study and to Prof Michael Hyland for the help in the 
data analysis; both contributed to the design of the study and 
writing of the manuscript.
Author contributions
Rupert Jones, Bruce J Kirenga, Wincelsas Katagira, Andy 
Barton, Jill Pooler, Alphonse Okwera, Richard Kasiita, and 
Siobhan Creanor contributed to the design of the study, analy-
sis, interpretation, and writing the paper. Bruce J Kirenga, 
Wincelsas Katagira, and Richard Kasiita also contributed to 
data collection. Doyo G Enki contributed to analysis, inter-
pretation, and writing the paper. Sally J Singh contributed to 
study design, intervention development, and paper review. 
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
Rupert Jones received grant from Astra Zeneca and personal 
fees from Astra Zeneca, Boehringer-Ingelheim, Chiesi, GSK, 
Novartis and Pfizer. Sally J Singh received funding from GSK 
and Novartis for advisory boards. Siobhan Creanor received 
grant from Plymouth University. The authors report no others 
conflicts of interest in this work.
References
1. World Health Organisation. [Homepage on the internet]. Global Status 
Report on Noncommunicable Diseases. 2014. Available from: http://
apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.
pdf?ua=1. Accessed October 5, 2017.
2. van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: the collid-
ing epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur 
Respir J. 2010;35(1):27–33.
3. Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H. An 
estimate of the prevalence of COPD in Africa: a systematic analysis. 
COPD. 2015;12(1):71–81.
4. van Gemert F, van der Molen T, Jones R, Chavannes N. The impact of 
asthma and COPD in sub-Saharan Africa. Prim Care Respir J. 2011; 
20(3):240–248.
5. Pasipanodya JG, McNabb SJ, Hilsenrath P, et al. Pulmonary impairment 
after tuberculosis and its contribution to TB burden. BMC Public Health. 
2010;10:259.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic
 O
bs
tr
uc
tiv
e 
P
ul
m
on
ar
y 
D
is
ea
se
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
14
1.
16
3.
10
6.
16
4 
on
 1
1-
D
ec
-2
01
7
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
3539
Pulmonary rehabilitation for post-TB lung disease in Uganda
 6. Harries AD, Ade S, Burney P, Hoa NB, Schluger NW, Castro JL. 
Successfully treated but not fit for purpose: paying attention to 
chronic lung impairment after TB treatment. Int J Tuberc Lung Dis. 
2016;20(8):1010–1014.
 7. Chakaya J, Kirenga B, Getahun H. Long term complications after com-
pletion of pulmonary tuberculosis treatment: a quest for a public health 
approach. J Clin Tuberc Other Mycobact Dis. 2016;3:10–12.
 8. Musafiri S, Dusabejambo V, Munganyinka B, et al. The aftermath of 
pulmonary tuberculosis: predictors of severe pulmonary sequelae and 
quality of life of patients visiting a tertiary level of care in Rwanda, 
East Africa. Austin J Pulm Respir Med. 2015;2(2):1027.
 9. Nici L, Donner C, Wouters E, et al; ATS/ERS Pulmonary Rehabilitation 
Writing Committee. American Thoracic Society/European Respira-
tory Society statement on pulmonary rehabilitation. Am J Respir Crit 
Care Med. 2006;173(12):1390–1413.
 10. Spruit M, Singh S, Garvey C, et al; ATS/ERS Task Force on Pulmo-
nary Rehabilitation. ATS/ERS task force on pulmonary rehabilitation. 
An official American Thoracic Society/European Respiratory Society 
statement: key concepts and advances in pulmonary rehabilitation. 
Am J Respir Crit Care Med. 2013;188(8):e13–e64.
 11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy 
for Diagnosis, Management, and Prevention of COPD. 2016. Available 
from: http://goldcopd.org/global-strategy-diagnosis-management-
prevention-copd-2016/. Accessed October 5, 2017.
 12. BTS Quality Standards Working Group. Quality Standards for Pulmonary 
Rehabilitation in Adults. British Thoracic Society Reports: British 
Thoracic Society; 2014:6(2). Available from: https://www.brit-thoracic.
org.uk/document-library/clinical-information/pulmonary-rehabilitation/
bts-quality-standards-for-pulmonary-rehabilitation-in-adults/. Accessed 
October 5, 2017.
 13. Muzembo Ndundu J, Nkakudulu Bikuku H, Frans A. Respiratory 
rehabilitation in patients with bronchial asthma and chronic obstruc-
tive pulmonary disease (COPD) in Kinshasa. Rev Pneumol Clin. 2001; 
57(3):209–218.
 14. de Grass D, Manie S, Amosum S. Effectiveness of a home-based pul-
monary rehabilitation programme in pulmonary function and health 
related quality of life for patients with pulmonary tuberculosis: a pilot 
study. Afr Health Sci. 2015;14(4):866–872.
 15. Muñoz-Torrico M, Rendon A, Centis R, et al. Is there a rationale for 
pulmonary rehabilitation following successful chemotherapy for tuber-
culosis? J Bras Pneumol. 2016;42(5):374–385.
 16. Ando M, Mori A, Esaki H, et al. The effect of pulmonary rehabilitation 
in patients with post-tuberculosis lung disorder. Chest. 2003;123(6): 
1988–1995.
 17. Tada A, Matsumoto H, Soda R, et al. Effects of pulmonary rehabilita-
tion in patients with pulmonary tuberculosis sequelae. Nihon Kokyuki 
Gakkai Zasshi. 2002;40(4):275–281.
 18. Betancourt-Peña J, Muñoz-Erazo BE, Hurtado-Gutiérrez H. Effect of 
pulmonary rehabilitation in quality of life and functional capacity in 
patients with tuberculosis sequela. Nova. 2015;13(24):47–54.
 19. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen 
mustards in the palliative treatment of carcinoma. With particular refer-
ence to bronchogenic carcinoma. Cancer. 1948;1(4):634–656.
 20. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. 
Usefulness of the medical research council (MRC) dyspnoea scale as 
a measure of disability in patients with chronic obstructive pulmonary 
disease. Thorax. 1999;54(7):581–586.
 21. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, 
Postma DS, Juniper EF. Development, validity and responsiveness of 
the clinical COPD questionnaire. Health Qual Life Outcomes. 2003; 
1(1):13.
 22. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
 23. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development 
of a shuttle walking test of disability in patients with chronic airways 
obstruction. Thorax. 1992;47(12):1019–1024.
 24. Whitney SL, Wrisley DM, Marchetti GF, Gee MA, Redfern MS, 
Furman JM. Clinical measurement of sit-to-stand performance in people 
with balance disorders: validity of data for the Five-Times-Sit-to-Stand 
Test. Phys Ther. 2005;85(10):1034–1045.
 25. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Ståhl E, van der 
Molen T. Health status measurement in COPD: the minimal clinically 
important difference of the clinical COPD questionnaire. Respir Res. 
2006;7:62.
 26. Meretta BM, Whitney SL, Marchetti GF, Sparto PJ, Muirhead RJ. The 
five times sit to stand test: responsiveness to change and concurrent 
validity in adults undergoing vestibular rehabilitation. J Vestib Res. 2006; 
16(4–5):233–243.
 27. Sohanpal R, Hooper R, Hames R, et al. S112 estimating participation 
rates of COPD patients in pulmonary rehabilitation and self-management 
programmes: the importance of defining participation. Thorax. 2012; 
67(suppl 2):A55.
 28. Hayton C, Clark A, Olive S, et al. Barriers to pulmonary rehabilitation: 
characteristics that predict patient attendance and adherence. Respir 
Med. 2013;107(3):401–407.
 29. National COPD Audit Programme. Pulmonary Rehabilitation: Steps 
to Breathe Better. London: Royal College of Physicians; 2016.
 30. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. 
Pulmonary rehabilitation for chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev. 2015;2:CD003793.
 31. Kon SS, Dilaver D, Mittal M, et al. The clinical COPD questionnaire: 
response to pulmonary rehabilitation and minimal clinically important 
difference. Thorax. 2014;69(9):793–798.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic
 O
bs
tr
uc
tiv
e 
P
ul
m
on
ar
y 
D
is
ea
se
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
14
1.
16
3.
10
6.
16
4 
on
 1
1-
D
ec
-2
01
7
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
